Tag
Tag: ADC Therapeutics
Update: ADC Therapeutics’ IPO Hits Above Target with €215M
It’s News Roundup Time! Big Data, RNA Therapies, and More …
ADC Therapeutics Cancels Nasdaq IPO Amidst Market Growth Fears
ADC Therapeutics and SOPHiA Genetics Team Up to Personalize Cancer Treatment
Update: Swiss Biotech’s Series E Expanded to €271M to Commercialize Antibody-Guided Cancer Chemotherapy
Top 10 Biotechs in Lausanne
Money, Money, Money! Europe’s Best-Funded Biotechs in 2018
New Antibody-Drug Conjugate Offers Hope to Hard-to-Treat Cancer Patients
Europe’s Brightest Stars: The 9 Best Biotech Companies of 2017
Swiss ADCs Show Impressive Responses for Lymphoma in Phase I
